相关实验视频
Updated: Jul 5, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
患有阿尔茨海默病和低tau负担的个体:特征和影响
Susan M Landau1, JiaQie Lee1, Alice Murphy1
1Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 19, 2024
概括
低水平在阿尔茨海默氏症 (AD) 患者中常见,这些患者有粉样β斑块. 这种低tau状态与并发症有关,影响认知障碍和AD疗法治疗选择.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 阿尔茨海默病的研究阿尔茨海默病的研究.
- 发现生物标志物的发现.
背景情况:
- 阿尔茨海默氏病 (AD) 在病理上是由异常的粉样β (Aβ) 和沉积定义的.
- 尽管Aβ阳性,但在AD途径上的很大一部分人表现出不升高的tau水平.
研究的目的:
- 研究粉样β阳性 (Aβ+) 个体的特征和区域模式,与高 (A+T+) 个体相比,低 (A+T-) 个体.
- 在AD的背景下,了解低tau状态的临床和人口学关联.
- 探索与水平相关的α-synuclein和认知功能之间的关系.
主要方法:
- 对397名粉样β阳性 (Aβ+) 个体的分析,分为无损或损伤.
- 基于全球tau水平,比较低tau (A+T-) 与高tau (A+T+) 的个体.
- 评估人口因素,心血管风险,α-synuclein和认知表现.
主要成果:
- 71%的没有受损的和42%的受损的Aβ+个体被归类为A+T-.
- 在受损个体中,A+T状态与年龄,男性性别和更高的心血管风险相关.
- 阿尔法-同核素与较差的认知有关,特别是在低tau组.
- 在特定的时间区域持续观察到较高的负荷,不管总体负荷的状况如何.
结论:
- 低陶氏是AD路径上粉样蛋白病理学个体的频繁发现.
- 伴随性疾病,如心血管风险因素,与低群体的认知障碍有关.
- 这些发现对于完善患者选择阿米洛伊德-β和定位疗法在阿尔茨海默病中至关重要.
相关概念视频
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551

